Clinical Research Directory
Browse clinical research sites, groups, and studies.
Exocrine Pancreatic Insufficiency's Prevalence in Active Crohn's Disease
Sponsor: Hospices Civils de Lyon
Summary
This study aims to assess the prevalence of exocrine pancreatic insufficiency (EPI) in a population of patients with active Crohn's disease. Studies already describe a prevalence rate around 18-66%. In this multicentric prospective study, we plan to compare EPI's prevalence at week 0 and week 14 of an induction phase of a biological therapy. The biological therapy will be initiate for an active Crohn's disease. Secondary outcomes will be: malnutrition's prevalence, and Crohn's disease activity level.
Official title: Exocrine Pancreatic Insufficiency's Prevalence in Active Crohn's Disease Treated by Biological Therapy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
50
Start Date
2019-11-15
Completion Date
2027-11-15
Last Updated
2026-01-02
Healthy Volunteers
No
Conditions
Interventions
Search for exocrine pancreatic insufficiency at week 0 and 12
We will collect 24 hours stool to search for steatorrhea, and to measure elastase and calprotectin. We will collect a total of 8 additional blood tubes (25mL), during regular blood sampling for a patient under biological therapy for a Crohn's disease. We will gather the total caloric and fat intake with a diet record.
Locations (1)
Service d'Hépato-Gastroentérologie, Centre Hospitalier Lyon-Sud, HCL
Pierre-Bénite, France